Biomea Fusion, Inc. (BMEA) Research

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

Market snapshot

Symbol
BMEA
Price
$1.18
Day change
-1.67%
Market cap
$70.2M
P/E ratio
-1.90x
52-week range
0.872-2.99
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$20.20

Peer companies

  • Adverum Biotechnologies, Inc. (ADVM)
  • ALX Oncology Holdings Inc. (ALXO)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Cibus, Inc. (CBUS)
  • Fractyl Health, Inc. Common Stock (GUTS)
  • Immunic, Inc. (IMUX)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • Repare Therapeutics Inc. (RPTX)

Recent insider activity

  • Faust Elizabeth — A-Award (196299 shares) on 2026-06-10
  • AGUIAR ERIC — A-Award (196299 shares) on 2026-06-10
  • Ray Sumita — A-Award (196299 shares) on 2026-06-10
  • Averill Julianne — A-Award (173711 shares) on 2026-06-10
  • Erdtmann Rainer M — A-Award (452512 shares) on 2026-04-01

Open Biomea Fusion, Inc. (BMEA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.